Original article. Potential risk of dihydroergotamine causing medicationoveruse headache: preclinical evidence

1. The International Classification of Headache Disorders: 2nd edition. Cephalalgia. 2004; 24 (Suppl 1): 9-160.Search in Google Scholar

2. Bigal ME, Rapoport AM, Sheftell FD, Tepper SJ, Lipton RB. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia. 2004; 24:483-90.10.1111/j.1468-2982.2004.00691.x15154858Open DOISearch in Google Scholar

3. Jonsson P, Hedenrud T, Linde M. Epidemiology of medication overuse headache in the general Swedish population. Cephalalgia. 2011; 31:1015-22.10.1177/033310241141008221628444Open DOISearch in Google Scholar

4. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc. 1945; 20:241-8.Search in Google Scholar

5. Dahlof C, Maassen Van Den Brink A. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment. Headache. 2012; 52:707-14.10.1111/j.1526-4610.2012.02124.x22444161Open DOISearch in Google Scholar

6. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache. 2006; 46(Suppl 4): S171-81.10.1111/j.1526-4610.2006.00601.x17078849Open DOISearch in Google Scholar

7. Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache. 2011; 51:507-17.10.1111/j.1526-4610.2011.01869.x21457235Open DOISearch in Google Scholar

8. Supornsilpchai W, le Grand MS, Srikiatkhachorn A. Cortical hyperexcitability and mechanism of medication-overuse headache. Cephalalgia. 2010; 30: 1101-9.10.1177/033310240935560020713560Open DOISearch in Google Scholar

9. Supornsilpchai W, le Grand MS, Srikiatkhachorn A. Involvement of pro-nociceptive 5-HT2A receptor in the pathogenesis of medication-overuse headache. Headache. 2010; 50:185-97.10.1111/j.1526-4610.2009.01591.x20039957Open DOISearch in Google Scholar

10. Goadsby PJ, Lipton RB, Ferrari MD. Migraine -- current understanding and treatment. N Engl J Med. 2002; 346:257-70.10.1056/NEJMra01091711807151Open DOISearch in Google Scholar

11. Bongsebandhu-Phubhakdi S, Phisonkulkasem T, Srikiatkhachorn A. Nociceptin/orphanin FQ modulates cortical activity and trigeminal nociception. Headache. 2011; 51:1245-53.10.1111/j.1526-4610.2011.01958.x21797854Open DOISearch in Google Scholar

12. Zhou L, Wang K, Tan W, Chen Y, Zuo X, Wen J, et al. Quantitative intracellular molecular profiling using a one-dimensional flow system. Anal Chem. 2006; 78: 6246-51.10.1021/ac060598e16944908Open DOISearch in Google Scholar

13. Ozdemir E, Gursoy S, Bagcivan I. The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. J Physiol Sci. 2012; 62:317-23.10.1007/s12576-012-0207-xOpen DOISearch in Google Scholar

14. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res. 1992; 597:321-30.10.1016/0006-8993(92)91489-2Search in Google Scholar

15. Storer RJ, Goadsby PJ. Microiontophoretic application of serotonin (5HT)1B/1D agonists inhibits trigeminal cell firing in the cat. Brain. 1997; 120:2171-7.10.1093/brain/120.12.2171Open DOISearch in Google Scholar

16. Bongsebandhu-phubhakdi S, Srikiatkhachorn A. Pathophysiology of medication-overuse headache: implications from animal studies. Curr Pain Headache Rep. 2012; 16:110-5.10.1007/s11916-011-0234-yOpen DOISearch in Google Scholar

17. Coppola G, Schoenen J. Cortical excitability in chronic migraine. Curr Pain Headache Rep. 2012; 16:93-100.10.1007/s11916-011-0231-1Open DOISearch in Google Scholar

18. Coppola G, Vandenheede M, Di Clemente L, et al. Somatosensory evoked high-frequency oscillations reflecting thalamo-cortical activity are decreased in migraine patients between attacks. Brain. 2005; 128: 98-103.10.1093/brain/awh334Open DOISearch in Google Scholar

19. van den Maagdenberg AMJM, Pietrobon DP, Pizzorusso T, Kaja S, Broos LA, Cesetti T, et al. A CACNA1a knockin migraine mouse model with increased susceptibility to cortical spreading depression. Neuron. 2004; 41:701-10.10.1016/S0896-6273(04)00085-6Open DOISearch in Google Scholar

20. Coppola G, Curr☐ A, Di Lorenzo C, Parisi V, Gorini M, Sava SL, et al. Abnormal cortical responses to somatosensory stimulation in medication-overuse headache. BMC Neurol. 2010; 10:126.10.1186/1471-2377-10-126302424821192822Open DOISearch in Google Scholar

21. Ferraro D, Vollono C, Miliucci R, Virdis D, De Armas L, Pazzaglia C, et al. Habituation to pain in “medication overuse headache”: a CO2 laser-evoked potential study. Headache. 2012; 52:792-807.10.1111/j.1526-4610.2012.02151.x22512411Open DOISearch in Google Scholar

22. De Felice M, Ossipov MH, Wang R, Lai J, Chichorro J, Meng I, et al. Triptan-induced latent sensitization: a possible basis for medication overuse headache. Ann Neurol. 2010; 67:325-37.Search in Google Scholar

23. Srikiatkhachorn A, Anthony M. Platelet serotonin in patients with analgesic-induced headache. Cephalalgia. 1996; 16:423-6.10.1046/j.1468-2982.1996.1606423.x8902251Open DOISearch in Google Scholar